Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.

Yang, Xingcheng; Ma, Ling; Zhang, Xiaoying; Huang, Liang; Wei, Jia

Yang, Xingcheng; Ma, Ling; Zhang, Xiaoying; Huang, Liang; Wei, Jia.

Afiliación

Yang X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.
Ma L; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, 430030, Hubei, China.
Zhang X; Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Huang L; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.
Wei J; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, 430030, Hubei, China.

Exp Hematol Oncol ; 11(1): 11, 2022 Mar 02.

Article en En | MEDLINE | ID: mdl-35236415

Palabras clave

AML transformation; Acute myeloid leukemia; Hypomethylating agent; Immune checkpoint; Myelodysplastic syndrome; Programmed cell death ligand-1; Programmed cell death-1

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Exp Hematol Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google